OTCM
NTBLQ
Market cap0kUSD
Jun 01, Last price
0.00USD
Name
Vascular Biogenics Ltd
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-41.60%
Rev. gr., 5y
-11.93%
Revenues
310k
+3,775.00%
Net income
-11m
L-21.82%
CFO
-14m
L+17.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||